Editor’s Choice: Hepatitis C Virus Postexposure Prophylaxis in the Healthcare Worker: Why Direct-Acting Antivirals Don’t Change a Thing
Clinical Infectious Diseases January 1, 2017 V.64 N.1 P.92-99
Susanna Naggie, David P. Holland, Mark S. Sulkowski, and David L. Thomas
1Duke Clinical Research Institute
2Duke University School of Medicine, Durham, North Carolina
3Emory University School of Medicine, Atlanta, Georgia
4Johns Hopkins School of Medicine, Baltimore, Maryland
Currently, 380 000–400 000 occupational exposures to blood-borne pathogens occur annually in the United States.
The management for occupational HIV or hepatitis B virus exposures includes postexposure prophylaxis (PEP) when necessary; however, PEP is not recommended for hepatitis C virus (HCV) exposures.
Recent approval of HCV direct-acting antivirals (DAAs) has renewed discussions as to whether these therapies could be used to prevent infection after exposure. There are no published studies addressing this question, but the prescribing of DAAs for PEP has been reported.
We will discuss the differences in transmission of the 3 most common blood-borne pathogens, the natural history of early HCV infection, and the scientific rationale for PEP.
In particular, we will discuss how the low feasibility of conducting an adequately powered clinical trial of DAA use for PEP and the low cost-effectiveness of such an intervention is not supportive of targeting limited resources for such use.
Entry filed under: Antivirales no HIV, Biología Molecular, Epidemiología, Health Care-Associated Infections, Hepatitis C, Infecciones nosocomiales, Metodos diagnosticos, Profilaxis Post-Exposición, REPORTS, Update.
Editor’s Choice: Coinfection With Zika and Dengue-2 Viruses in a Traveler Returning From Haiti, 2016: Clinical Presentation and Genetic Analysis Editor’s Choice: Editorial Commentary: Decision Science at Work: The Case of Hepatitis C Virus Postexposure Prophylaxis